Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?. Issue 25 (19th June 2020)

• Record Type: Journal Article
• Authors: Michalska, Anna; Gorczyca, Iwona; Chrapek, Magdalena; Kapłon-Cieślicka, Agnieszka; Uziębło-Życzkowska, Beata; Starzyk, Katarzyna; Jelonek, Olga; Budnik, Monika; Gawałko, Monika; Krzesiński, Paweł; Jurek, Agnieszka; Scisło, Piotr; Kochanowski, Janusz; Kiliszek, Marek; Gielerak, Grzegorz; Filipiak, Krzysztof J.; Opolski, Grzegorz; Wożakowska-Kapłon, Beata
• Other Names: Tu. Wen-Jun section editor.
• Is Part Of: Medicine. Volume 99:Issue 25(2020)
• Publication Date: 2020-06-19
• Subjects: anticoagulation -- atrial fibrillation -- intermediate risk -- scales; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000020570
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The CHA2 DS2 -VASc scale does not include potential risk factors for left atrial appendage thrombus (LAAT) formation such as a form of atrial fibrillation (AF) and impaired kidney function. The real risk of thromboembolic complications in AF patients is still unclear as well as an optimal anticoagulant treatment in males with a CHA2 DS2 -VASc score of 1 and females with a CHA2 DS2 -VASc score of 2. The aim of this study was to compare the predictive value of the CHA2 DS2 -VASc scale and other scales to estimate the risk of LAAT formation in AF patients treated with non-vitamin K oral anticoagulants (NOACs) and to assess the prevalence of thrombi in patients at intermediate risk of stroke. The observational study included consecutive patients with a diagnosis of non-valvular AF treated with NOACs, admitted to 3 high-reference institutions between 2013 and 2018. All individuals underwent transoesophageal echocardiography before cardioversion or ablation. Out of 1163 enrolled AF patients (62.1% male, mean age 62 years) the LAAT had been detected in 50 individuals (4.3%). Among patients with LAAT, 1 patient (2.0%) was classified as a low-risk category, 9 (18.0%) were at intermediate-risk, and 40 (80.0%) were at high risk of thromboembolic complications according to CHA2 DS2 -VASc scale. All patients were treated with NOACs: 51.0% rivaroxaban, 47.1% dabigatran, and 1.9% apixaban. Patients at intermediate stroke-risk with detected LAAT had higher R2 CHADS2 score (2.1 ± 1.2 vs 1.2 ± 0.8, P = .007), higher CHA2 DS2 -VASc-RAF score (6.4 ± 4.4 vs 3.7 ± 2.6, P = .027) and more often had an estimated glomerular filtration rate below 56 mL/min/1.73 m 2 (44.4% vs 13.2%, P = .026) compared to patients without LAAT. The receiver operating characteristics revealed that the CHA2 DS2 -VASc-RAF scale had better predictive ability to distinguish between patients with and without LAAT in the study group than CHA2 DS2 -VASc ( P = .0006), CHADS2 ( P = .0006) and R2 CHADS2 scale ( P = .0140). The CHA2 DS2 -VASc scale should be supplemented with an assessment of renal function and form of AF to improve stroke risk estimation. The application of additional scales to estimate the risk of LAAT might be especially useful among males with a CHA2 DS2 -VASc score of 1 and females with a CHA2 DS2 -VASc score of 2.